NICE (UK) positive for Venclyxto (venetoclax) with obinutuzumab for untreated chronic lymphocytic leukaemia – Abbvie

NICE(UK): Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if the companies provide the technologies according to the commercial arrangements.

Why the recommendation was made: This evaluation partially reviews the evidence for venetoclax plus obinutuzumab for untreated CLL. It reviews new evidence collected for the population in the managed access agreement for NICE technology appraisal guidance 663. This includes evidence from clinical trials and from people having the treatment through managed access in the Cancer Drugs Fund in England. Usual treatment for the population in the managed access agreement is venetoclax plus ibrutinib. Venetoclax plus obinutuzumab has not been directly compared in a clinical trial with venetoclax plus ibrutinib. But indirect comparisons suggest that they are likely to work as well as each other. There are some uncertainties in the clinical evidence, which make the cost-effectiveness evidence uncertain. But the cost-effectiveness evidence suggests that venetoclax plus obinutuzumab has similar or lower costs than venetoclax plus ibrutinib. In NICE technology appraisal guidance 663, NICE considered venetoclax plus obinutuzumab to be cost effective for the population outside the managed access agreement. So, venetoclax plus obinutuzumab can be used for untreated CLL.